Clinical Trials Directory

Trials / Completed

CompletedNCT04657263

Impact of the COVID-19 Pandemic on Vaccination

Impact of the COVID-19 Pandemic on Vaccination in Patients at Risk of Infection

Status
Completed
Phase
Study type
Observational
Enrollment
500 (actual)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The vaccination policy is drawn up in France by the French Minister of Health, who makes public the vaccination schedule after the opinion of the High Authority of Health. Currently according to the 2019 immunization schedule, the dTP vaccine is the only mandatory in the general population with recalls in adults aged 25, 45, 65 and every 10 years. In 2011, the Ministry of Health estimated that only 50.5% of the general population was up to date against dTP. Two vaccines are recommended for person at risk of infection according to the current vaccine schedule: the flu vaccine and the pneumococcal vaccine. In fact, influenza and pneumococcal disease are more frequent and more serious in patients with chronic diseases (diabetes, cardiac insufficiency..) compared to the general population. The vaccination coverage rate of at-risk populations is dramatically below the vaccination coverage targets set by the Ministry of Health. Indeed, there are many barriers to vaccination, medical and para-medical barriers, but also individual barriers. The current COVID-19 pandemic has identified people at risk of severe infection and death risk, particularly those with co-morbidities (diabetes, cardiovascular disease, etc.). Thus, this pandemic may have contributed to change in patients' perceptions regarding both the risk of infection and the potential interest and benefit of vaccination.

Conditions

Interventions

TypeNameDescription
OTHERVaccine coverage assessmentVaccine coverage assessment

Timeline

Start date
2020-11-01
Primary completion
2021-05-01
Completion
2021-05-30
First posted
2020-12-08
Last updated
2021-10-25

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04657263. Inclusion in this directory is not an endorsement.